Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ETGlobeNewsWire · Oct 8, 2026
AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowZacks Investment Research · Oct 6, 2026
Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionZacks Investment Research · Oct 2, 2026
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIODefense World · Sep 4, 2026
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial FlywheelSeeking Alpha · Aug 20, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIOPRNewsWire · Aug 13, 2026Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$1.65 | -$1.69 | Miss |
| Apr 29, 2026 | -$1.81 | -$1.69 | Beat |
| Feb 12, 2026 | -$1.97 | -$1.85 | Beat |
| Oct 30, 2025 | -$1.93 | -$1.78 | Beat |
| Jul 31, 2025 | -$1.74 | -$1.93 | Miss |
| May 1, 2025 | -$1.80 | -$1.55 | Beat |